TY - JOUR
T1 - The Role of MicroRNAs in Resistance to Current Pancreatic Cancer Treatment
T2 - Translational Studies and Basic Protocols for Extraction and PCR Analysis
AU - Garajová, Ingrid
AU - Le Large, Tessa Y S
AU - Giovannetti, Elisa
AU - Kazemier, Geert
AU - Biasco, Guido
AU - Peters, Godefridus J
PY - 2016
Y1 - 2016
N2 - Pancreatic ductal adenocarcinoma (PDAC) is a common cause of cancer death and has the worst prognosis of any major malignancy, with less than 5 % of patients alive 5-years after diagnosis. The therapeutic options for metastatic PDAC have changed in the past few years from single agent gemcitabine treatment to combination regimens. Nowadays, FOLFIRINOX or gemcitabine with nab-paclitaxel are new standard combinations in frontline metastatic setting in PDAC patients with good performance status. MicroRNAs (miRNA) are small, noncoding RNA molecules affecting important cellular processes such as inhibition of apoptosis, cell proliferation, epithelial-to-mesenchymal transition (EMT), metastases, and resistance to common cytotoxic and anti-signaling therapy in PDAC. A functional association between miRNAs and chemoresistance has been described for several common therapies. Therefore, in this review, we summarize the current knowledge on the role of miRNAs in the resistance to current anticancer treatment used for patients affected by metastatic PDAC.
AB - Pancreatic ductal adenocarcinoma (PDAC) is a common cause of cancer death and has the worst prognosis of any major malignancy, with less than 5 % of patients alive 5-years after diagnosis. The therapeutic options for metastatic PDAC have changed in the past few years from single agent gemcitabine treatment to combination regimens. Nowadays, FOLFIRINOX or gemcitabine with nab-paclitaxel are new standard combinations in frontline metastatic setting in PDAC patients with good performance status. MicroRNAs (miRNA) are small, noncoding RNA molecules affecting important cellular processes such as inhibition of apoptosis, cell proliferation, epithelial-to-mesenchymal transition (EMT), metastases, and resistance to common cytotoxic and anti-signaling therapy in PDAC. A functional association between miRNAs and chemoresistance has been described for several common therapies. Therefore, in this review, we summarize the current knowledge on the role of miRNAs in the resistance to current anticancer treatment used for patients affected by metastatic PDAC.
KW - Drug Resistance, Neoplasm
KW - Humans
KW - Journal Article
KW - MicroRNAs
KW - Pancreatic Neoplasms
KW - Paraffin Embedding
KW - Real-Time Polymerase Chain Reaction
KW - Research Support, Non-U.S. Gov't
KW - Reverse Transcription
KW - Tissue Fixation
U2 - https://doi.org/10.1007/978-1-4939-3347-1_10
DO - https://doi.org/10.1007/978-1-4939-3347-1_10
M3 - Article
C2 - 26910074
SN - 1064-3745
VL - 1395
SP - 163
EP - 187
JO - Methods in Molecular Biology
JF - Methods in Molecular Biology
ER -